NATUS MEDICAL INC Form 10-K/A March 12, 2018

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 10-K/A

Amendment No. 1

Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended \circ December 31, 2017

OR

Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period

from to .

Commission

file number:

000-33001

NATUS MEDICAL INCORPORATED

(Exact name of Registrant as specified in its charter)

Delaware 77–0154833 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification Number)

6701 Koll Center Parkway, Suite 120, Pleasanton, CA 94566

(Address of principal executive offices) (Zip Code)

(925) 223-6700

(Registrant's telephone number, including area code)

Securities Registered Pursuant to Section 12(b) of the Act:

Title of each class Name of each exchange on which registered

Common Stock, \$0.001 par value per share

The NASDAQ Stock Market LLC

(Nasdaq Global Select Market)

Securities Registered Pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes \circ No "

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes "No \circ

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such requirements for the past 90 days. Yes ý No "Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ý No "

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or

information statements incorporated by reference in Part III of the Form 10-K or any amendment to this Form 10-K. ý Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act:

Large accelerated filer ý Accelerated filer ¬

Non-accelerated filer ¬ Smaller reporting company ¬ (Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes "No ý

As of June 30, 2017, the last business day of Registrant's most recently completed second fiscal quarter, there were 33,149,439 shares of Registrant's common stock outstanding, and the aggregate market value of such shares held by non-affiliates of Registrant (based upon the closing sale price of such shares on the Nasdaq Global Select Market on June 30, 2017) was \$1,236,474,075. Shares of Registrant's common stock held by each executive officer and director and by each entity that owns 5% or more of Registrant's outstanding common stock have been excluded in that such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.

On February 18, 2018, the registrant had 33,160,428 shares of its common stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

The Registrant has incorporated by reference, into Part III of this Form 10-K, portions of its Proxy Statement for the 2018 Annual Meeting of Stockholders.

EXPLANATORY NOTE

This Amendment No. 1 on Form 10-K/A (this "Amendment") to the registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, initially filed with the Securities and Exchange Commission ("SEC") on March 1, 2018 (the "Original Filing"), is being filed to amend and restate Item 15(a)(3) in Part IV of the Original Filing in order to update the Exhibit Index referred to therein.

Also included in this Amendment are (i) signature page and (ii) certifications required of the principal executive officer and principal financial officer under Section 302 of the Sarbanes-Oxley Act of 2002. Because no financial statements are contained within this Amendment, we are not including certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

No attempt has been made in this Amendment to modify or update the other disclosures presented in the Original Filing. This Amendment does not reflect events occurring after the filing of the Original Filing or modify or update those disclosures, including the exhibits to the Original Filing, affected by subsequent events. Accordingly, this Amendment should be read in conjunction with the Original Filing and our other filings made with the SEC.

PART IV

ITEM 15. Exhibits, Financial Statement Schedules (a)(3) Exhibits

The Exhibits listed in the Index to Exhibits, which appears immediately following the signature page and is incorporated herein by reference, are filed as part of this 10-K/A.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report on Form 10-K to be signed on its behalf by the undersigned thereunto duly authorized.

NATUS MEDICAL INCORPORATED

By /s/ JAMES B. HAWKINS James B. Hawkins President and Chief Executive Officer

By /s/ JONATHAN A. KENNEDY Jonathan A. Kennedy

Executive Vice President and Chief Financial Officer

Dated: March 12, 2018

EXHIBIT INDEX

Exhibit No.	Evhibit	Incorporated By Reference Filing Exhibit No. File No. File Date		File Date	
Exilibit No.	Natus Medical Incorporated Amended and Restated Certificate	·			
<u>3.1</u>	of Incorporation	S-1	3.1.1	333-44138	8/18/2000
<u>3.2</u>	Certificate of Amendment of the Amended and Restated				
	Certificate of Incorporation	8-K	3.1	000-33001	9/13/2012
	Natus Medical Incorporated Certificate of Designation of				
<u>3.3</u>	Rights, Preferences and Privileges of Series A Participating	8-A	3.1.2	000-33001	9/6/2002
	Preferred Stock				
<u>3.4</u>	Bylaws of Natus Medical Incorporated	8-K	3.1	000-33001	6/18/2008
<u>3.5</u>	Amended and Restated Bylaws of Natus Medical Incorporated	10-Q	3.1	000-33001	5/9/2012
<u>10.1</u>	Form of Indemnification Agreement between Natus Medical	S-1	10.1	333-44138	8/18/2000
	<u>Incorporated and each of its directors and officers</u>	5 1			
<u>10.2</u> *	Natus Medical Incorporated Amended and Restated 2000	8-K	10.1	000-33001	1/4/2006
	Stock Awards Plan				
10.2.1*	Form of Option Agreement under the Amended and Restated	S-1	10.3.1	333-44138	8/18/2000
	2000 Stock Awards Plan Form of Postrioted Stock Purchase Agreement under the	10-Q	10.2		
<u>10.2.2</u> *	Form of Restricted Stock Purchase Agreement under the Amended and Restated 2000 Stock Awards Plan			000-33001	8/9/2006
	Form of Restricted Stock Unit Agreement under the Amended				
<u>10.2.3</u> *	and Restated 2000 Stock Awards Plan	10-K	10.2.3	000-33001	3/14/2008
<u>10.3</u> *	Natus Medical Incorporated 2000 Director Option Plan	10-Q	10.02	000-33001	5/9/2008
	Form of Option Agreement under the 2000 Director Option				
<u>10.3.1</u> *	Plan	S-1	10.4.1	333-44138 8/	5/18/2000
10.4*	Natus Medical Incorporated 2000 Supplemental Stock Option	S-1	10.15	333-44138	2/9/2001
<u>10.4</u> *	<u>Plan</u>	3-1			
10.4.1*	Form of Option Agreement for 2000 Supplemental Stock	S-1	10.15.1	333-44138	2/9/2001
	Option Plan	5-1	10.13.1	333 44130	2/ // 2001
<u>10.5</u> *	Natus Medical Incorporated 2000 Employee Stock Purchase	8-K	10.2	000-33001	1/4/2006
	Plan and form of subscription agreement thereunder				
<u>10.6</u> *	[Amended] 2011 Stock Awards Plan	14-A	_	000-33001	4/20/2011
<u>10.6.1</u> *	Form of Stock Option Award Agreement under the [Amended]	10-Q	10.1	000-33001	11/7/2011
10.6.2*	2011 Stock Plan Form of Restricted Stock Award Purchase Agreement	10-Q	10.2	000-33001	11/7/2011
10.6.2*	Form of Restricted Stock Unit Agreement	10-Q 10-Q		000-33001	
10.0.3 10.7*	2011 Employee Stock Purchase Plan	14-A		000-33001	
10.7.1*	2011 Employee Stock Purchase Plan Subscription Agreement	14-A		000-33001	
	Form of Employment Agreement between Natus Medical				0 0 1 1
<u>10.8</u> *	Incorporated and each of its executive officers other than its	10-K	10.10	000-33001	3/10/2009
	Chief Executive Officer and Chief Financial Officer				

Exhibit No.	Exhibit		orated By R Exhibit No		File Date
<u>10.8.1</u> *	Form of Amendment to Employment Agreement between Natus Medical Incorporated and each of its executive officers other than its Chief Executive Officer and Chief Financial Officer	10-K		000-33001	3/16/2015
<u>10.9</u> *	Amended employment agreement between Natus Medical Incorporated and its Chief Executive Officer, James B. Hawkins dated April 19, 2013	8-K	99.1	000-33001	4/22/2013
10.10*	Form of Employment Agreement between Natus Medical Incorporated and Jonathan A. Kennedy dated April 8, 2013	10-Q	10.1	000-33001	8/8/2013
<u>10.11</u>	Credit Agreement between Natus Medical Incorporated and CitiBank, NA dated October 9, 2015	8-K	10.1	000-33001	10/9/2015
10.12	Agreement For the Acquisition of Medical Devices between Medix ICSA and the Ministry of Health of the Republic of Venezuela dated October 15, 2015	10-Q		000-33001	2/29/2016
10.13	Amendment to Agreement For the Acquisition of Medical Devices between Medix ICSA and the Ministry of Health of the Republic of Venezuela dated October 15, 2015	10-Q	10.2	000-33001	11/3/2016
<u>10.14</u>	Credit Agreement, dated September 23, 2016, between the Company, JP Morgan Chase Bank, N.A. and Citibank, N.A.	10-Q	10.1	000-33001	11/3/2016
<u>10.15</u>	Master Purchase Agreement, dated September 25, 2016, between GN Hearing A/S, GN Nord A/S and the Company	10-Q	10.3	000-33001	11/3/2016
16.1 21.1#	Letter Regarding Change in Certifying Accountant Significant Subsidiaries of the Registrant	8-K	16.1	000-33001	3/28/2014
23.1#	Consent of Independent Registered Public Accounting Firm				
<u>24.1</u> <u>31.1</u> #	Power of Attorney (included on signature page) Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002				
<u>31.2</u> #	<u>Certification of Principal Financial Officer pursuant to Section</u> 302 of the Sarbanes-Oxley Act of 2002				
31.3	<u>Certification of Principal Executive Officer pursuant to Section</u> 302 of the Sarbanes-Oxley Act of 2002				
<u>31.4</u>	<u>Certification of Principal Financial Officer pursuant to Section</u> 302 of the Sarbanes-Oxley Act of 2002				
<u>32.1</u> #	Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002				

Incorporated	By	Reference
--------------	----	-----------

Exhibit No. Exhibit	Filing Exhibit No. File No. File Date
---------------------	---------------------------------------

101.INS# **XBRL** Instance Document

101.SCH# XBRL Taxonomy Extension Schema Document

XBRL Taxonomy Extension Label Calculation Linkbase 101.CAL#

Document

101.DEF# XBRL Taxonomy Extension Definition Document 101.LAB# XBRL Taxonomy Extension Label Linkbase Document

101.PRE# XBRL Taxonomy Extension Presentation Linkbase Document

Indicates a management contract or compensatory plan or arrangement

Previously filed with Annual Report on Form 10-K for year ended December 31, 2017